SCHEMBL60332

SCHEMBL60332

CCOC(=O)CCC[C@H]1CCC2CC1C2(C)C

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.42
MAPK14 Q16539 1/20 0.42
CAMK1D Q8IU85 1/20 0.42
ALOX15 P16050 2/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP1A2 P05177 1/20 0.39
SMYD3 Q9H7B4 1/20 0.37
EPHX2 P34913 10/20 0.37
HDAC6 Q9UBN7 3/20 0.36
S1PR1 P21453 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14452949 0.82 MAPK14 (0.46) RETMAPK14CAMK1DALOX15EPHX2
SCHEMBL14452946 0.82 MAPK14 (0.46) RETMAPK14CAMK1DALOX15EPHX2
SCHEMBL14452955 0.82 MAPK14 (0.46) RETMAPK14CAMK1DALOX15EPHX2
SCHEMBL61209 0.81 RET (0.47) RETMAPK14CAMK1DALOX15EPHX2
SCHEMBL59970 0.81 RET (0.47) RETMAPK14CAMK1DALOX15EPHX2
SCHEMBL11604726 0.76 MAPK14 (0.50) RETMAPK14CAMK1DALOX15EPHX2
SCHEMBL8991630 0.75 RET (0.40) RETMAPK14CAMK1DALOX15EPHX2
SCHEMBL11604288 0.74 RET (0.49) RETMAPK14CAMK1DALOX15EPHX2
SCHEMBL10285179 0.74 RET (0.46) RETMAPK14CAMK1DALOX15EPHX2
SCHEMBL18513498 0.74 RET (0.46) RETMAPK14CAMK1DALOX15EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446021-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof DOGWOOD PHARMACEUTICALS, INC. (US) 2016-09-20 US disclosed
US-20150313873-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof DOGWOOD PHARMACEUTICALS, INC. 2015-11-05 US disclosed
US-9120754-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof DOGWOOD PHARMACEUTICALS, INC. (US) 2015-09-01 US disclosed
US-20120129837-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof ALLERGAN SALES, LLC 2012-05-24 US disclosed
US-8129519-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof ALLERGAN SALES, LLC 2012-03-06 US disclosed
US-20100137354-A1 DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF ALLERGAN SALES, LLC 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129837-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof WNT1, CTNND1, CTNNB1 RET 1772/4885MAPK14 301/4885CAMK1D 3281/4885
US-20150313873-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof WNT1, CTNND1, CTNNB1 RET 1772/4885MAPK14 301/4885CAMK1D 3281/4885
US-20100137354-A1 DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF WNT1, CTNND1, CTNNB1 RET 1772/4885MAPK14 301/4885CAMK1D 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.